ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Adverse events and anti-TNF therapy"

  • Abstract Number: 1852 • 2012 ACR/ARHP Annual Meeting

    Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A Case/Non-Case Study in a Nationwide Pharmacovigilance Database

    Johana Béné1, Guillaume Moulis2, Marine Auffret3, Claire Fessier1, Guillaume Lefevre4 and Sophie Gautier1, 1Lille University Hospital, Lille Pharmacovigilance Regional Centre, Lille, France, 2Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, 3Pharmacology, Lille University Hospital, Lille Pharmacovigilance Regional Centre, Lille, France, 4Lille University Hospital, Internal Medicine Department, Lille, France

    Background/Purpose: Cases of alopecia occurring on TNF-alpha antagonists have been described. Nevertheless, no epidemiological study has been conducted to assess the link between TNF-alpha antagonists…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Chicago, IL

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.